146929-33-1

Basic information

• Product Name: CYCLAZOSIN HYDROCHLORIDE
• Synonyms: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) decahydroquinoxaline;Cyclazosin monohydrochloride;cis-1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline monohydrochloride;Cyclazosin hydrochloride Solution, 100ppm
• CAS NO: 146929-33-1
• Molecular Formula: C23H27N5O4
• Molecular Weight: 473.95
• Mol File: 146929-33-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 691.1oC at 760 mmHg
• Flash Point: 371.7oC
• Appearance: white/solid
• Vapor Pressure: 2.43E-19mmHg at 25°C
• Solubility: H2O: 1.8 mg/mL
• CAS DataBase Reference: CYCLAZOSIN HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLAZOSIN HYDROCHLORIDE(146929-33-1)
• EPA Substance Registry System: CYCLAZOSIN HYDROCHLORIDE(146929-33-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 146929-33-1(Hazardous Substances Data)

Usage

Description

Cyclazosin hydrochloride is a prazosin-related α1-adrenoceptor antagonist that acts on α1-, α2-adrenoceptors, dopamine D2, and 5-HT1A receptors. It is a pharmaceutical compound with potential applications in the medical field due to its ability to interact with various receptors.

Uses

Used in Pharmaceutical Industry:
Cyclazosin hydrochloride is used as a therapeutic agent for the treatment of various medical conditions. Its action as an α1-adrenoceptor antagonist allows it to be potentially effective in managing conditions related to the adrenergic system, such as hypertension and benign prostatic hyperplasia (BPH).
Additionally, its interaction with dopamine D2 and 5-HT1A receptors suggests potential applications in the treatment of neurological and psychiatric disorders, such as schizophrenia and Parkinson's disease, where modulation of these receptors is crucial for symptom management.

InChI:InChI=1/C23H27N5O4.ClH/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18;/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26);1H

Upstream product

• 23680-84-4 2-chloro-6,7-dimethoxyquinazolin-4-amine 
• 118948-26-8 cis-decahydroquinoxaline 
• 527-69-5 2-furancarbonyl chloride 

Relevant articles and documents

USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the alpha1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at th

Structure-Activity Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on α-Blocking Activity

Several prazosin-related compounds have been synthesized and evaluated for their blocking activity toward α-adrenoreceptors.The structural modification performed on the prazosin structure included the replacement of the piperazine ring with 2,3-dialkylpiperazine or 1,2-cyclohexanediamine moieties to characterize a lipophilic binding pocket in the α1 adrenoreceptor surface.Cyclohexanediamine derivatives 3-6 were almost devoid of potency and selectivity, whereas dialkylpiperazine compounds 7-14 showed high affinity and selectivity toward α1-adrenoreceptors.The cis derivative 13 (cyclazosin) was the most potent and selective with an α1/α2 selectivity ratio value of 7800.The particular trend of antagonist activity within cis/trans stereoisomeric compounds not only supports the presence of a lipophilic binding area on α1-adrenoreceptor surface but also suggests that the lipophilic pocket is endowed with a well-defined size and spatial orientation.The most active compound of the series, 13, was tested also in vivo for antihypertensive activity on spontaneously hypertensive rats.It showed an interesting long-lasting hypotensive effect, very similar to that of doxazosin, which was statistically significant 12 h after oral administration.